Search

Displaying results 811 - 820 of 10000 in total
  1. Drug

    Cabotegravir

    go.drugbank.com/drugs/DB11751
    ApprovedInvestigational

    [A227668,L31193] Cabotegravir was granted FDA approval on 21 January 2021 in combination with rilpivirine to treat HIV-1 infection in virologically suppressed individuals. … [L31198] While previously administered once monthly only, this combination product was granted FDA approval for dosing every two months on February 01, 2022 [L40084] and without the need for an oral lead-in

    Products: Vocabria 30 mg Film Kaplı Tablet, 30 ADET, Vocabria 400 mg/2 ml Enjeksiyonluk Uzatılmış Salımlı Süspansiyon, 1 ADET
  2. Drug

    Digoxin

    go.drugbank.com/drugs/DB00390
    ApprovedInvestigational

    [L9143] This drug originates from the foxglove plant, also known as the _Digitalis_ plant[T610], studied by William Withering, an English physician and botanist in the 1780s. … [A178234] Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954.

    Categories: Compounds used in a research, industrial, or household settingInternational brands: Digocard-G
  3. Drug

    Edetate copper disodium

    go.drugbank.com/drugs/DB14599
    Experimental

    Synonyms: Copper versenate, Copper disodium edetate
  4. Drug

    Tinidazole

    go.drugbank.com/drugs/DB00911
    ApprovedInvestigational

    A nitroimidazole antitrichomonal agent effective against Trichomonas vaginalis, Entamoeba histolytica, and Giardia lamblia infections.

    Mixtures: TRİVAG 300 MG / 200 MG/ 100 MG OVÜL, 3 ADET, GYNOMAX XL 200 MG/ 300 MG/100 MG VAJINAL OVÜL, 3 ADETProducts: TINIDAZOL 20% SUSPENSION, TINIDAZOL 200 MG/ML SUSPENSION
  5. Drug

    Etelcalcetide

    go.drugbank.com/drugs/DB12865
    ApprovedInvestigational

    Etelcalcetide was approved (trade name Parsabiv) for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis in February, 2017. … Etelcalcetide is a calcimimetic drug for the treatment of secondary hyperparathyroidism in patients undergoing hemodialysis.

    Products: PARSABIV SOLUTION FOR INJECTION 10 mg/2 mL, PARSABİV 10 MG/2 ML I.V. ENJEKSİYONLUK ÇÖZELTİ, 1 ADET
  6. Drug

    Galcanezumab

    go.drugbank.com/drugs/DB14042
    ApprovedInvestigational

    [L42060] It is unknown if galcanezumab has an effect on pregnancy outcomes. A pregnancy exposure registry has been established to evaluate the safety of this drug in pregnant women.[L42060] … [A33112] Galcanezumab was approved by the FDA in September 2018, and is indicated for the preventive treatment of migraine and the treatment of episodic cluster headache.

    Products: EMGALITY SOLUTION FOR INJECTION IN PRE-FILLED PEN 120 MG/ML, Pontevia 120 mg solution for injection in pre-filled pen
  7. Drug

    Fremanezumab

    go.drugbank.com/drugs/DB14041
    ApprovedInvestigational

    [L11779] Along with other recently approved anti-CGRP therapies such as [galcanezumab], [erenumab], and the oral CGRP antagonist [ubrogepant], fremanezumab represents an important step forward in the treatment … [L11749] It was developed by Teva Pharmaceuticals USA and approved by the FDA in September 2018.

    Products: AJOVY SOLUTION FOR INJECTION IN PRE-FILLED PEN 225 MG/1.5ML, AJOVY SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 225 MG/1.5ML
  8. Drug

    Testosterone undecanoate

    go.drugbank.com/drugs/DB13946
    ApprovedInvestigational

    [L35970] It was developed via fatty acid esterification of testosterone in order to achieve orally administer testosterone. … [A246594] There are oral and intramuscular formulations available for testosterone undecanoate: both formulations are indicated for testosterone replacement therapy in adult males with hypogonadism.

    Products: VIRIGEN TESTOCAPS 40 MG KAPSUL, 30 ADET, Andriol Testocaps 40 mg - Kapseln
  9. Drug

    Burosumab

    go.drugbank.com/drugs/DB14012
    ApprovedInvestigational

    Burosumab (KRN23) is an entirely human monoclonal IgG1 antibody that binds excess fibroblast growth factor 23 (FGF23) and has been successfully tested in clinical trials in children with X-linked hypophosphatemic … Food and Drug Administration approved Crysvita (burosumab) in April 2018.

    Products: CRYSVITA® SOLUCIÓN PARA INYECCIÓN 20 MG/ML, CRYSVITA® SOLUTION FOR INJECTION 10 MG/ML
  10. Drug

    Doxorubicin

    go.drugbank.com/drugs/DB00997
    ApprovedInvestigational

    Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970. … [A257614] Thanks to its efficacy and broad effect, doxorubicin was approved by the FDA in 1974 to treat a variety of cancer, including but not limited to breast, lung, gastric, ovarian, thyroid, non-Hodgkin

    Synonyms: (8S-cis)-10-((3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione, (1S,3S)-3-glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosideProducts: DOXORUBICINA 10 MG/5 ML, DOXORUBICINA 50 MG / 15 ML